It is in selling value-added food
Hua S, Marks E, Schneider JJ, Keely S (2015) Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease, selective targeting to diseased versus healthy tissue
Cost should factor into the decision, but clinical appropriateness remains paramount
Because retatrutide isnt commercially approved yet the cost structure works differently from standard prescription drugs and knowing whats inside the number matters before any comparison makes sense
Side effects of Retatrutide as they relate to this product remain unknown
Open questions also include an unresolved debate in the peer-reviewed literature about the implications of BPC-157s pro-angiogenic activity for cancer-relevant signaling pathways, raised in a 2025 literature review and disputed by the original research group